Market News AIOpen the app

MAIA Biotechnology shared promising results from its Phase 2 study on a new lung cancer treatment.

TrialRead the original at SEC EDGAR
Good for MAIA

MAIA reported an 88% disease control rate, with Part C results aligned with Parts A and B in a larger group. The ongoing Phase 2 study has not shown approval, but these consistent results favor MAIA.

MAIA · MAIA Biotechnology, Inc.

AI read · Good for MAIA

The AI's read

The results across a larger group make the disease-control signal more consistent. The study is still ongoing, and MAIA says further data may support an FDA filing. No approval has been reported.

Get alerts for MAIA

Follow MAIA Biotechnology, Inc. (MAIA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MAIA
Free on the App Store and Google Play, or on the web.